NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZOMIG-ZMT (zolmitriptan) by AstraZeneca is serotonin 1b receptor agonists [moa]. First approved in 2001.
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMIG-ZMT (zolmitriptan) is an orally disintegrating tablet formulation of a serotonin 1b/1d receptor agonist approved in 2001 for acute migraine treatment. It works by constricting cranial blood vessels and inhibiting neuropeptide release to rapidly abort migraine episodes. The ZMT formulation enables rapid disintegration without water, improving convenience for migraine sufferers.
LOE Approaching
As an established product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on defending market share and managing transition planning.
Mechanism of Action
Serotonin 1b Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Started May 2010
10 enrolled
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
Started Sep 2002
2,114 enrolled
Migraine
Career Relevance
Working on ZOMIG-ZMT offers limited career growth potential given the product's LOE-approaching lifecycle and zero linked job openings. This role is better suited for professionals seeking stabilization or preparation for transition planning rather than expansion and launch excitement.
Brand Manager
Worked on ZOMIG-ZMT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.